J&J ends hepatitis B and HPV portions of Bavarian Nordic collab

Johnson & Johnson’s Janssen ended its collaboration and licensing agreements with Bavarian Nordic concerning vaccines for hepatitis B virus and human papillomaviruses.

J&J and the Danish vaccines biotech will continue their tie-up as it relates to HIV and Ebola, Janssen said Monday. The duo announced the HPV pact in December 2015 at a total potential value of $171 million, and the hepatitis B and HIV work came via a July 2017 agreement worth up to $879 million.

The Big Pharma cited the “widespread uptake of effective, preventive vaccines” against HPV as reasoning for dropping that portion of the pair’s collab. The company will not continue R&D efforts on HPV, an infectious area largely cornered by Merck’s Gardasil.

Meanwhile, J&J will continue to investigate hepatitis B through its existing pipeline, which includes two Phase II combination therapy studies. The two companies never…
Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.


*